Auris Medical Holding AG (NASDAQ:EARS)‘s stock had its “buy” rating reaffirmed by equities researchers at Roth Capital in a note issued to investors on Saturday. They presently have a $5.00 target price on the biotechnology company’s stock.

Several other brokerages have also weighed in on EARS. Needham & Company LLC cut their price objective on shares of Auris Medical Holding AG from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, March 14th. ValuEngine downgraded shares of Auris Medical Holding AG from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $3.42.

Shares of Auris Medical Holding AG (EARS) opened at 0.735 on Friday. The stock’s market cap is $32.58 million. Auris Medical Holding AG has a one year low of $0.60 and a one year high of $5.45. The firm has a 50 day moving average of $0.66 and a 200 day moving average of $0.89.

Auris Medical Holding AG (NASDAQ:EARS) last posted its quarterly earnings results on Thursday, May 11th. The biotechnology company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.08. On average, equities research analysts predict that Auris Medical Holding AG will post ($0.72) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Auris Medical Holding AG (EARS) Rating Reiterated by Roth Capital” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/07/03/auris-medical-holding-ag-ears-coverage-initiated-by-analysts-at-roth-capital.html.

A number of large investors have recently bought and sold shares of EARS. UBS Oconnor LLC acquired a new stake in Auris Medical Holding AG during the first quarter worth $909,000. Perceptive Advisors LLC purchased a new position in Auris Medical Holding AG during the first quarter valued at $368,000. Sabby Management LLC purchased a new position in Auris Medical Holding AG during the first quarter valued at $133,000. Morgan Stanley boosted its position in Auris Medical Holding AG by 37,537.6% in the first quarter. Morgan Stanley now owns 150,174 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 149,775 shares during the last quarter. Finally, Sofinnova Management VIII L.L.C. boosted its position in Auris Medical Holding AG by 34.4% in the first quarter. Sofinnova Management VIII L.L.C. now owns 7,818,175 shares of the biotechnology company’s stock valued at $7,193,000 after buying an additional 2,000,000 shares during the last quarter. Institutional investors and hedge funds own 29.06% of the company’s stock.

Auris Medical Holding AG Company Profile

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with MarketBeat.com's FREE daily email newsletter.